Cannady Steven B, Cavanaugh Kelly A, Lee Shih-Yuan, Bukowski Ronald M, Olencki Thomas E, Stevens Glen H J, Barnett Gene H, Suh John H
Department of Otolaryngology, Brain Tumor Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):253-8. doi: 10.1016/s0360-3016(03)00818-6.
To determine the benefit of whole brain radiotherapy (WBRT) and the use of the Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis (RPA) classification system in patients with brain metastases from renal cell carcinoma.
We identified 46 consecutive patients with brain metastases from renal cell carcinoma who were treated with WBRT at the Cleveland Clinic Foundation between 1983 and 2000. We reviewed their charts for patient and tumor characteristics and categorized them according to the RTOG RPA classes.
The median follow-up and survival time for all 46 patients (15 women and 31 men) was 3.0 months. The median radiation dose was 3000 cGy in 10 fractions. Patients who received higher radiation doses (>3000 cGy) survived longer than those who received 3000 cGy or less than 3000 cGy (8.5 months vs. 2.7 months vs. 0.4 months, p = 0.0289). However, the Karnofsky performance status and RPA class were confounding factors in these data. The median survival for patients by RTOG RPA class was 8.5 months for Class I (n = 2), 3 months for Class II (n = 37), and 0.6 months for Class III (n = 7, p = 0.0834).
Despite the relatively poor prognosis of patients who receive WBRT alone, it appears that they benefit from this palliative treatment. The RTOG RPA classification system may be a useful tool in assessing prognosis in this patient population.
确定全脑放疗(WBRT)的益处以及放射治疗肿瘤学组(RTOG)递归分区分析(RPA)分类系统在肾细胞癌脑转移患者中的应用。
我们确定了1983年至2000年间在克利夫兰诊所基金会接受WBRT治疗的46例连续的肾细胞癌脑转移患者。我们查阅了他们的病历以了解患者和肿瘤特征,并根据RTOG RPA类别对他们进行分类。
所有46例患者(15名女性和31名男性)的中位随访时间和生存时间为3.0个月。中位放射剂量为3000 cGy,分10次给予。接受较高放射剂量(>3000 cGy)的患者比接受3000 cGy或低于3000 cGy的患者存活时间更长(8.5个月对2.7个月对0.4个月,p = 0.0289)。然而,卡诺夫斯基功能状态和RPA类别是这些数据中的混杂因素。根据RTOG RPA类别,I类患者(n = 2)的中位生存期为8.5个月,II类患者(n = 37)为3个月,III类患者(n = 7)为0.6个月(p = 0.0834)。
尽管仅接受WBRT的患者预后相对较差,但他们似乎从这种姑息治疗中获益。RTOG RPA分类系统可能是评估该患者群体预后的有用工具。